observed that GLUT3-armored CAR T-cells demonstrated increased uptake of the glucose analog 2NBDG, greater release of effector cytokines, and enhanced tumor cell killing in vitro compared to GLUT1-armored CAR T-cells. This evidence concerns the gene SLC2A3 and neoplasm.